Euretina Congress
Euretina Congress
October 02, 2018
1 min watch
Save

VIDEO: DME non-responders to anti-VEGF may benefit from dexamethasone implant

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

VIENNA — At the Euretina meeting, Catharina Busch, MD, discusses the results of a study showing patients with diabetic macular edema who do not respond to an anti-VEGF loading dose may benefit from dexamethasone steroid treatment with the Ozurdex (Allergan) implant.